Table 1 Susceptibility of P. aeruginosa isolates from cystic fibrosis infections to rumen microbiome-derived AMPs and comparator antibiotics measured by minimal inhibitory concentration and minimal bactericidal concentration.

From: Microbiome-derived antimicrobial peptides offer therapeutic solutions for the treatment of Pseudomonas aeruginosa infections

    

Lynronne 1

Lynronne 2

Lynronne 3

P15s

Levofloxacin

Polymyxin B

Source ID

Geographical location

Genome sequence

Details

MIC

MBC

MIC

MBC

MIC

MBC

MIC

MBC

MIC

MBC

MIC

PA01

Genome sequenced isolate

Yes

High growth density at 15 h, high virulence

32

32

64

64

32

64

64

128

0.125

0.5

1

LES400

CF, Liverpool, U.K.

Yes

Transmissible, low growth density at 15 h, low virulence

16

32

16

32

32

32

32

32

1

2

LES431

CF, Liverpool, U.K.

Yes

Transmissible, low growth density at 15 h, low virulence

8

16

16

32

64

128

128

128

0.5

4

1–4

LESB58

CF, Liverpool, U.K.

Yes

Transmissible, low growth density at 15 h, low virulence

16

32

128

128

32

64

128

256

0.125

0.5

C3719

CF, Manchester, U.K.

Yes

Transmissible, paediatric, low growth density at 15 h, high virulence

64

128

32

32

32

64

64

128

0.125

0.5

AMT0060-2

Paediatric CF, Seattle, WA

No

Late isolate, high growth density at 15 h, high virulence, MIC of Ofloxacin, Carbenicillin and Tobramycin affected

64

64

32

32

128

128

128

128

0.125

2

AES-1R

Paediatric CF, Melbourne, Australia

Yes

Transmissible, low growth density at 15 h, high virulence.

64

64

64

128

256

256

512

>512

0.125

2

NH57388A

CF. Denmark

Yes

Low growth density at 15 h, low growth density at 15 h, alginate hyper-producer

32

64

32

64

128

256

256

512

0.5

4